Full Press Release Details
Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates
Company Plans to File Q3 2020 10-Q on
San Francisco, CA (November 10, 2020): Jaguar Health,
Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference
call on Monday, November 16, 2020 at 8:30 a.m. Eastern Time to review third-quarter 2020 financials and provide business updates.
Dial-In Instructions for Investor Call
When: Monday, November 16, 2020 at 8:30
Dial-in (US Toll Free): 866-548-4713
Dial-in (International): 323-794-2093
Conference ID number: 8490376
Live webcast on the investor relations section
of Jaguar's website (click here)
Replay Instructions for Investor Call
Dial-in (US Toll Free): 844-512-2921
Dial-in (International): 412-317-6671
Replay Pin Number: 8490376
Replay of the webcast on the investor relations
section of Jaguar's website (click here)
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company
focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with
GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing
and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest
areas. Our Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious
diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA
For more information about Jaguar, please visit https://jaguar.health.
For more information about Napo, visit www.napopharma.com.
Mytesi (crofelemer) is an antidiarrheal indicated
for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi
is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi .
If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate
therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo
were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information
are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi , is a botanical (plant-based) drug extracted
and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established
a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements." These include statements regarding the expectation that Jaguar will host a conference call on November 16, 2020,
and the expectation that the Company will file its quarterly report on Form 10-Q on November 16, 2020 for the quarterly period
ended September 30, 2020. In some cases, you can identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "aim," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe," "estimate,"
"predict," "potential" or "continue" or the negative of these terms or other similar expressions.
The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely
on its current expectations and projections about future events. These forward-looking statements speak only as of the date of
this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified
and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update
or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances
Source: Jaguar Health, Inc.